Participating Faculty

New and Emerging Therapies for Multiple Sclerosis and the Role of Managed Care

This supplement to The American Journal of Managed Care reviews the efficacy, safety, and limitations of current first-line therapies for multiple sclerosis (MS), describes the mechanisms of action, efficacy, and safety of 4 emerging oral therapies for MS, and discusses the potential impact of oral MS agents on patients, physicians, and managed care organizations.

Faculty

Edward J. Fox, MD, PhD

Central Texas Neurology Consultants

Round Rock, Texas

Robert J. Lipsy, PharmD, FASHP, BCPS

Clinical Assistant Professor

University of Arizona

College of Pharmacy

Tucson, Arizona

Clyde E. Markowitz, MD

Director, Multiple Sclerosis Center

Associate Professor of Neurology

University of Pennsylvania

Philadelphia, Pennsylvania

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Edward J. Fox, MD, PhD

Consultant/advisory board:

Bayer, Biogen Idec, EMD Serono, Genzyme, Pfizer, Opexa, Teva

Grants:

Biogen Idec, EMD Serono, Genzyme, Opexa, Ono, sanofi-aventis, Teva

Honoraria/lectureship/meeting and conference attendance:

Bayer, Biogen Idec, EMD Serono, Teva

Robert J. Lipsy, PharmD, FASHP, BCPS, has nothing relevant to disclose.

Clyde E. Markowitz, MD

Consultant/lectureship:

Bayer, Biogen Idec, EMD Serono, Novartis, Teva, Wyeth

Grants:

Bayer, Biogen Idec, EMD Serono, Novartis, Teva

The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Download PDF: Participating Faculty